# eNRGy (NCT02912949)

> A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)

No report yet. It can be ordered.

- Drugs tested: zenocutuzumab
- Indication: solid tumors harboring NRG1 fusion

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02912949
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Partner Therapeutics, Inc.
- Conditions: Solid Tumours Harboring NRG1 Fusion; NSCLC Harboring NRG1 Fusion; Pancreatic Cancer Harboring NRG1 Fusion; NRG1 Fusion
- Interventions: zenocutuzumab (MCLA-128)
- Enrollment: 250
- Primary outcome: Objective overall response rate (ORR) as per local investigator's assessment
- Primary outcome: Duration of response per RECIST v1.1 as per local Investigator's assessment.

## Indexed commentary on eNRGy so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 31
- Podcasts: 4
- YouTube: 3

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=enrgy-nct02912949

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02912949", "email": "<work email>"}; the inbox owner confirms by the emailed link.